FIREFLOX™ 500

Levofloxacin is the L-isomer of ofloxacin and a third-generation fluoroquinolone antibiotic. It is pharmacologically distinct from second-generation fluoroquinolones (ciprofloxacin, ofloxacin) in three clinically important ways: superior gram-positive activity (particularly against Streptococcus pneumoniae), enhanced atypical organism coverage, and a once-daily dosing profile.

Like all fluoroquinolones, levofloxacin exerts bactericidal activity by inhibiting DNA gyrase and topoisomerase IV — but its selectivity for the bacterial topoisomerase IV in gram-positive organisms is higher than ciprofloxacin's, explaining its superior S. pneumoniae activity. This makes levofloxacin the preferred fluoroquinolone for community-acquired pneumonia where S. pneumoniae is the dominant pathogen.

Levofloxacin achieves an oral bioavailability of approximately 99% — among the highest of any antibiotic — enabling once-daily dosing that maintains 24-hour bactericidal activity above the MIC for susceptible organisms. Tissue penetration is excellent into lung parenchyma (achieving AUC/MIC ratios of >30 for S. pneumoniae), prostate, ENT tissues, and urinary tract.

The oxycarb dye provides batch authentication for anti-counterfeiting purposes — an important quality assurance feature for a DPCO-regulated product in high-demand markets.

FIREFLOX™ 500 is indicated for moderate-to-severe community-acquired infections in adults, particularly respiratory, urological, and ENT infections where once-daily dosing, superior pneumococcal coverage, and atypical organism activity are clinically required.

Community-Acquired Pneumonia (Primary Indication): Levofloxacin 500mg once daily for 7–14 days is a IDSA/ATS guideline-recommended monotherapy for outpatient CAP management in patients with comorbidities or prior antibiotic use. It covers S. pneumoniae (including penicillin-resistant strains), H. influenzae, M. catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila — the complete spectrum of community respiratory pathogens.

Complicated Urinary Tract Infections and Pyelonephritis: Superior to ciprofloxacin for UTIs involving S. pneumoniae or gram-positive organisms (rare but clinically important) while maintaining equivalent gram-negative coverage for E. coli and Klebsiella.

Acute Bacterial Sinusitis: Levofloxacin covers the full spectrum of sinusitis pathogens including resistant S. pneumoniae — indicated for moderate-severe sinusitis unresponsive to first-line amoxycillin or co-amoxiclav.

Chronic Bacterial Prostatitis: Excellent prostate penetration at concentrations well above the MIC for susceptible uropathogens — 500mg once daily for 28 days is a guideline-recommended regimen.

ENT Infections: Complicated otitis media, mastoiditis, and periorbital/orbital cellulitis where resistant S. pneumoniae or gram-negative organisms require fluoroquinolone therapy.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.